Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Panekès Partners SGR S.p.A.. (9/27/21). "Press Release: Panakès Partners Appoints Dr. Rob Woodman as Partner to Lead Biotech Investment". Milan.

Organisations Organisation Panakès Partners »Purple Fund«
  Group Panakès Partners (Group)
  Organisation 2 Takeda Ventures Inc. (TVI)
  Group Takeda (Group)
Products Product Panakés Partners »Purple Fund«
  Product 2 BIOTECH
  Index term 2 Panakès Partners–SEVERAL: investment, 202107 first closing €150m of Purple Fund
Persons Person Woodman, Rob (Panakès Partners 202109– Partner to lead biotech team before Takeda Ventures + Imperial Innovations)
  Person 2 Landi, Fabrizio (Panakés Partners 202107 Managing Partner + Co-Founder)
     


> Dr. Rob Woodman brings 15 years of experience in life science investing and a track record of success in both institutional and corporate venture capital

> Panakès successful first closing at €150 million of its second Fund enabled the extension of its investment activity into biotech

> Panakès newly created biotech team is actively investing in next generation innovative biotechs

> Panakès will invest in Biotech companies at the forefront of global innovation with the potential to transform patient care


Panakès Partners, the leading Italian venture capital firm in the Life Sciences sector, is pleased to announce that Dr. Rob Woodman has joined Panakès as a Partner, to lead the firm’s newly created biotech investment team.

The appointment of Dr. Woodman follows the recent first closing at €150 million ($175 million) of Panakès’ second fund (named the Purple Fund), which is focused on both Biotech and Medtech. As a result, Panakès is now ideally placed to selectively deploy capital into the next generation of innovative start-ups.

Dr. Woodman has global experience in biotech gained at both institutional and corporate venture firms, encompassing de novo start-up through to growth investments. He has a track record of supporting value creation in all of these settings as demonstrated by multiple acquisitions and NASDAQ listings of the companies he has invested in.

Dr. Woodman comes to Panakès Partners with a long track record as a successful healthcare investor. Prior to joining Panakes, he was Senior Partner at Takeda Ventures and also Head of Genesis Labs, Takeda R&D's internal incubator, since 2018. Prior to Takeda, he was a Partner in the Healthcare Investment team at Touchstone Innovations (formerly Imperial Innovations) in London (UK). He started his venture career at Sofinnova Partners in Paris where he became Principal in the life science team.

Dr Woodman has led numerous investments and sat on the Board of many international biotech companies, including Inivata Inc. (acquired by NeoGenomics), Enterprise Therapeutics Ltd (acquired by Roche), Emendo Inc (acquired by Anges), and BioMx Inc. (Nasdaq: PHGE).

Dr. Woodman's experience of creating, building, and managing several start-ups, an activity that is a key element of the Panakès Purple Fund investment strategy, is complimented by his strong academic background, including an M.Sc. in Biochemistry from the University of Oxford and a PhD in Oncology from the University of Cambridge.

“We are delighted to have Rob join the team at this exciting moment for Panakès - Rob brings a wealth of experience in the biotech field, complementing our existing team's capabilities in medtech and diagnostics. Led by Rob, the Panakès biotech team will support leading biotech entrepreneurs and founders to create companies able to transform patient care,” said Fabrizio Landi, President of Panakès. “In the context of the recent first close of Panakès second fund and the creation of our strong and experienced biotech team, we are ideally positioned to contribute to the growth of companies active in the development of new therapies and vaccines.”

“Panakès has established a strong track record and solid international credibility since it was created,” commented Dr. Rob Woodman, “I am delighted to join the Panakès’ team, as it extends its activities into biotech. The team’s strategy will be to support the growth of entrepreneurial companies who will reshape healthcare globally by addressing real medical needs, saving lives, and providing a better quality of life for patients. By achieving these goals, the fund aims to generate value for both investors and for society as a whole.”


***


About Panakès Partners

Panakès is a Venture Capital firm with the ultimate goal of providing a better life to people all around the world, by providing both financial and business support to build the next generation of game-changing technologies companies in the field of Life Sciences. Panakès invest in ambitious start-ups and SMEs with innovative products globally, with a focus on Europe, US and Israel. Panakès HQ is in Milan, Italy.

www.panakes.it


Contacts

Panakès Partners
news@panakes.it


MEDiSTRAVA Consulting
Sylvie Berrebi, David Dible
panakes@medistrava.com
Tel: +44 (0)20 7638 9571

   
Record changed: 2021-10-07

Advertisement

Picture [iito] No Content Marketing 650x80px

More documents for Panakès Partners (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80




» top